Cochrane · systematic review · CD013453
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Cameron, LB, Hitchen, N, Chandran, E, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 7.1%Low 3 · 21.4%Moderate 4 · 28.6%High 6 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
ALK inhibitor compared to any cytotoxic chemotherapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Population: advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival: all participants ALK inhibitor vs any cytotoxic chemotherapy | HR 0.45 [0.4, 0.52] | 6 studies · 1611 participants | High |
Progression‐free survival in people with central nervous system disease ALK inhibitor vs any cytotoxic chemotherapy | HR 0.51 [0.41, 0.62] | 6 studies · 581 participants | High |
Overall adverse events ALK inhibitor vs any cytotoxic chemotherapy | RR 1.01 [1, 1.03] | 5 studies · 1404 participants | Low Downgraded: risk of bias, imprecision |
Grade 5 adverse events (excluding progressive disease) ALK inhibitor vs any cytotoxic chemotherapy | RR 2.03 [0.89, 4.66] | 6 studies · 1611 participants | Low Downgraded: imprecision |
Overall survival ALK inhibitor vs any cytotoxic chemotherapy | HR 0.84 [0.72, 0.97] | 6 studies · 1611 participants | High |
Overall response rate ALK inhibitor vs any cytotoxic chemotherapy | RR 2.43 [2.16, 2.75] | 6 studies · 1611 participants | Moderate Downgraded: inconsistency |
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) ALK inhibitor vs any cytotoxic chemotherapy | HR 0.52 [0.44, 0.6] | 5 studies · 1504 participants | High |
Next‐generation ALK inhibitor compared to crizotinib for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
Population: advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival: overall population Next‐generation ALK inhibitor vs crizotinib | HR 0.39 [0.32, 0.46] | 5 studies · 1263 participants | High |
Progression‐free survival in people with central nervous system disease Next‐generation ALK inhibitor vs crizotinib | HR 0.25 [0.19, 0.34] | 5 studies · 406 participants | High |
Overall adverse events Next‐generation ALK inhibitor vs crizotinib | RR 1 [0.98, 1.01] | 5 studies · 1263 participants | Moderate Downgraded: risk of bias |
Grade 5 adverse events (excluding progressive disease) Next‐generation ALK inhibitor vs crizotinib | RR 0.85 [0.49, 1.47] | 5 studies · 1263 participants | Low Downgraded: imprecision |
Overall survival Next‐generation ALK inhibitor vs crizotinib | HR 0.71 [0.56, 0.9] | 5 studies · 1263 participants | Moderate Downgraded: inconsistency |
Overall response rate Next‐generation ALK inhibitor vs crizotinib | RR 1.18 [1.1, 1.25] | 5 studies · 1229 participants | Moderate Downgraded: risk of bias |
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) Next‐generation ALK inhibitor vs crizotinib | HR 1.1 [0.72, 1.68] | 1 study · 303 participants | Very low Downgraded: risk of bias, imprecision, indirectness |